Helicobacter pylori bacterial enzymes

Helicobacter pylori bacterial enzymes are a collective group of proteins essential for the survival, colonization, and pathogenesis of the bacterium within the human gastric environment. The most prominent enzyme in this group is urease, which catalyzes the hydrolysis of urea into ammonia and carbon dioxide, effectively neutralizing local gastric acid to create a habitable microenvironment for the pathogen (Mobley et al., 1995, Microbiology and Molecular Biology Reviews). Other critical enzymes include DNA gyrase, which manages DNA supercoiling during replication, and various enzymes involved in peptidoglycan synthesis and protein translation (Kusters et al., 2006, Clinical Microbiology Reviews). These enzymes serve as the primary targets for standard eradication therapies, which typically combine multiple antibiotics such as amoxicillin and clarithromycin with acid-suppressing agents (Chey et al., 2017, American Journal of Gastroenterology). Chronic enzymatic activity and the associated secretion of virulence factors lead to persistent mucosal inflammation, significantly increasing the risk of peptic ulcers and gastric malignancies (NIH, 2022). The rising prevalence of multi-drug resistant H. pylori strains targeting these enzymatic pathways remains a major challenge in global clinical management (WHO, 2017).

Other names

H. pylori enzymesHelicobacter pylori proteinsGastric helicobacter enzymesH. pylori enzymatic targets

Drugs targeting these enzymes act by inhibiting bacterial cell wall synthesis (beta-lactams), inhibiting protein synthesis via the 30S or 50S ribosomal subunits (tetracyclines, macrolides), inhibiting DNA gyrase and topoisomerase IV (fluoroquinolones), or inducing DNA strand breakage through toxic intermediate metabolites (nitroimidazoles) (StatPearls, 2023; American College of Gastroenterology, 2017).